What Revolution Medicines, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 79 | 158 |
| Total trades | 88 | 214 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 252,365 | 1,124,364 |
| Disposed | 380,710 | 1,158,414 |
| Net activity | −128,345 | −34,050 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Sandler Alan B. | Chief Development Officer | Sep 29 | Open-market sale · S | −301 | $204.72 | −$61.6K | 52,559 |
| Sandler Alan B. | Chief Development Officer | Sep 29 | Open-market sale · S | −1,199 | $203.91 | −$244K | 52,860 |
| Sandler Alan B. | Chief Development Officer | Sep 29 | Open-market sale · S | −1,000 | $202.81 | −$203K | 54,059 |
| Sandler Alan B. | Chief Development Officer | Sep 29 | Open-market sale · S | −1,609 | $201.72 | −$325K | 55,059 |
| Sandler Alan B. | Chief Development Officer | Sep 29 | Open-market sale · S | −2,200 | $200.82 | −$442K | 56,668 |
| Sandler Alan B. | Chief Development Officer | Sep 29 | Exercise / conversion · M | +6,000 | $58.84 | +$353K | 58,868 |
| Mancini Anthony | See Remarks | Sep 25 | Open-market sale · S | −3,121 | $200.54 | −$626K | 39,765 |
| Mancini Anthony | See Remarks | Sep 25 | Exercise / conversion · M | +3,121 | $33.62 | +$105K | 42,886 |
| Cislini Jeff | SVP & General Counsel | Sep 25 | Open-market sale · S | −765 | $207.32 | −$159K | 51,776 |
| Mancini Anthony | See Remarks | Sep 24 | Open-market sale · S | −587 | $200.00 | −$117K | 39,765 |
| Anderson Elizabeth M | Director | Sep 22 | Open-market sale · S | −100 | $195.15 | −$19.5K | 4,333 |
| Anderson Elizabeth M | Director | Sep 22 | Open-market sale · S | −1,500 | $194.59 | −$292K | 4,433 |
| Anderson Elizabeth M | Director | Sep 22 | Open-market sale · S | −2,648 | $193.44 | −$512K | 5,933 |
| Anderson Elizabeth M | Director | Sep 22 | Open-market sale · S | −4,985 | $192.54 | −$960K | 8,581 |
| Anderson Elizabeth M | Director | Sep 22 | Open-market sale · S | −910 | $191.85 | −$175K | 13,566 |
| Anderson Elizabeth M | Director | Sep 22 | Exercise / conversion · M | +5,070 | $1.12 | +$5.68K | 14,476 |
| Mancini Anthony | See Remarks | Sep 18 | Open-market sale · S | −1,764 | $196.94 | −$347K | 40,352 |
| Kelsey Stephen Michael | See Remarks | Sep 16 | Open-market sale · S | −5,484 | $199.30 | −$1.09M | 286,307 |
| Kelsey Stephen Michael | See Remarks | Sep 16 | Open-market sale · S | −85 | $195.01 | −$16.6K | 291,791 |
| Cislini Jeff | SVP & General Counsel | Sep 16 | Open-market sale · S | −3,314 | $199.30 | −$660K | 52,541 |
Loading...